Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis

• Published in: International journal of clinical pharmacy 2020-08, Vol.42 (4), p.1217-1226
• Main Authors: Huerta-García, Ana Patricia, Medellín-Garibay, Susanna Edith, Ortiz-Álvarez, Arturo, Magaña-Aquino, Martín, Rodríguez-Pinal, Cristian Jazmín, Portales-Pérez, Diana Patricia, Romano-Moreno, Silvia, Milán-Segovia, Rosa del Carmen
• Format: Article
• Language: English
• Subjects: Acetyltransferase; Body mass index; Body weight; Enzymes; Gene polymorphism; Genetic factors; Genotype & phenotype; High-performance liquid chromatography; Internal Medicine; Isoniazid; Medicine; Medicine & Public Health; N-Acetyltransferase; Patients; Pharmacokinetics; Pharmacy; Phenotypes; Research Article; Single-nucleotide polymorphism; Stochasticity; Tuberculosis
• ISSN: 2210-7703; 2210-7711
• DOI: 10.1007/s11096-020-01086-1

Background The standardized doses of isoniazid in therapy against tuberculosis are determined based on total body weight, without considering genetic polymorphisms of the metabolic enzyme N-acetyltransferase-2 that contribute to the wide pharmacokinetic variability of isoniazid. Objective The aim of this work was to build a population pharmacokinetic model of isoniazid in Mexican patients with tuberculosis to characterize typical estimates of pharmacokinetics, as well as inter-individual and residual variability of isoniazid considering the genetic factors associated with the N-acetyltransferase-2 enzyme. Setting A prospective study was conducted at the Department of Internal Medicine in Hospital Central, San Luis Potosí, México. Methods Plasma concentrations of isoniazid were measured by high performance liquid chromatography. The acetylator phenotype was predicted through single nucleotide polymorphisms in the N-acetyltransferase-2 gene. Genetic, anthropometric and clinical covariates were used to develop a pharmacokinetic model. Main outcome measure Isoniazid plasma concentration. Results A total of 69 patients with tuberculosis were included. Blood samples were drawn from 20 min to 12 h post dose to determinate the isoniazid plasma concentration. Typical pharmacokinetics parameters were characterized through two-compartment open model with first-order absorption and linear elimination. Clearance was different for each predicted N-acetyltransferase-2 phenotype being 11.4, 19.2 and 27.4 L/h for slow, intermediate and rapid acetylators, respectively. Central volume of distribution was determined as 1.5 * body mass index (L). Through the application of the model, external validation was performed and initial dose regimen of isoniazid is proposed based on stochastic simulations. Conclusion A validated population pharmacokinetic model of isoniazid was developed in Mexican patients with tuberculosis. Through the application of the final model, initial dose recommendations were provided considering body mass index and N-acetyltransferase-2 phenotype.